Seungkirl Ahn

Nov 30, 2023 | nature.com | Robert J. Lefkowitz |Howard A. Rockman |Paul J. Shim |Samuel E. Liu |Seungkirl Ahn |Sudarshan Rajagopal | +3 more

arising from T. Benkel et al. Nature Communications https://doi.org/10.1038/s41467-022-34765-w (2022)The introduction of β-adrenergic receptor blockers, “β-blockers”, as a treatment for heart failure decades ago was a major advance in cardiovascular medicine1,2,3,4. Moreover, it has been clear for a number of years that some β-blockers with “intrinsic sympathomimetic activity” (ISA) due to weak partial agonist activity mediated through G protein stimulation did not share this salutary effect5,6.